Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8815544 | 0.89 | SLC1A3 (0.42) | LTA4HEPHX2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8114978 | 0.82 | CETP (0.41) | SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19 | |
| SCHEMBL21068681 | 0.81 | LTA4H (0.46) | LTA4HEPHX2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10965779 | 0.81 | TSHR (0.44) | SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19 | |
| SCHEMBL29087906 | 0.80 | LTA4H (0.45) | LTA4HEPHX2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4488619 | 0.80 | LTA4H (0.45) | LTA4HEPHX2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2300063 | 0.79 | LTA4H (0.44) | LTA4HEPHX2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28342870 | 0.79 | LTA4H (0.44) | LTA4HEPHX2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28342919 | 0.79 | LTA4H (0.44) | LTA4HEPHX2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8114209 | 0.78 | PPARG (0.42) | SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229636-B1 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | claimed |
| US-20200317783-A1 | BISPECIFIC ANTIBODY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-1997902-B1 | SCREENING METHOD | UNIV HIROSHIMA (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8329420-B2 | Screening method for a substance that binds to an intracellular region of TLR4 | HIROSHIMA UNIVERSITY (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| EP-2260869-A2 | Pharmaceutical product | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20090317833-A1 | Screening Method | HIROSHIMA UNIVERSITY (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090062355-A1 | Pharmaceutical Product | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-03-05 | — | — | US | disclosed |
| EP-2018855-A1 | PHARMACEUTICAL AGENT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018872-A1 | PHARMACEUTICAL PRODUCT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1997902-A1 | SCREENING METHOD | Hiroshima University (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1495756-A1 | SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT | Takeda Chemical Industries, Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040009168-A1 | Multidose antibody formulation | PROTEIN DESIGN LABS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-5021439-A | Senile dementia and memory dysfunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| US-4952212-A | Ocular treatment | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-28 | — | — | US | disclosed |
| US-4912215-A | Cyclic structure with a secondary amide in ring | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062355-A1 | Pharmaceutical Product | ATF1, ATF4, TLR8 | LTA4H 916/4885EPHX2 1650/4885SLC1A3 3242/4885 |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | SQLE, FDFT1, PTGIS | LTA4H 46/4885EPHX2 528/4885SLC1A3 4378/4885 |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | LTA4H 1257/4885EPHX2 3198/4885SLC1A3 2121/4885 |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | LTA4H 1279/4885EPHX2 3302/4885SLC1A3 2119/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | LTA4H 916/4885EPHX2 1650/4885SLC1A3 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.